← SynDRA
MIBEFRADIL
SynDRA canonical compound SYN0002377 — structure-anchored drug synonym record
| Clinical phase | Withdrawn |
|---|
| Primary target(s) | CACNA1G |
|---|
| Mechanism of action | T-type calcium channel blocker |
|---|
All known targets
- CACNA1H
- CACNA1G
- CACNA1I
- CACNA1C
- CATSPER2
- CATSPER4
- CATSPER3
- CATSPER1
- SCN9A
- SCN5A
- ANO1
- KCNH2
Mechanisms of action (all sources)
- T-type calcium channel blocker
- CACNA1H BLOCKER
- Voltage-gated T-type calcium channel blocker
- CACNA1G BLOCKER
- CACNA1I BLOCKER
- ANO1 INHIBITOR
- CACNA1C ANTAGONIST
- CACNA1G ANTAGONIST
- CACNA1H PORE BLOCKER
- CACNA1I ANTAGONIST
- CATSPER1 INHIBITOR
- CATSPER2 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- HTR1A
- SLC6A3
- OPRM1
- ESR1
- DRD3
- DRD1
- CYP2J2
- CYP2C19
- CHRM2
- CYP2D6
- ADRA1A
- SMAD3
- PGR
- MAPK1
- MAPT
- MPHOSPH8
- MTOR
- NFE2L2
- NPC1
- NPSR1
- UBE2N
- PDE3A
- PDE4A
- TP53
- SLC6A4
- PMP22
- THPO
- TDP1
- LMNA
- PTGS1
- TBXA2R
- RAB9A
- SNCA
- SLC6A2
- SMPD1
- MAOA
- ABCB11
- KDR
- IDH1
- ADORA1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- 5HT2A
- RAD52
- M4K2
- MDM2
- MDM4
- MDR1
- MK01
- NOD2
- NR1I2
- NSD2
- PRGR
- RARA
- KSYK
- RIPK2
- SCN10A
- SCN11A
- SCN1A
- SCN3A
- SCN7A
- SCN8A
- SYK
- TAAR1
- LOX12
- KCNK2
- ALOX12
- CP2D6
- ANDR
- APAF
- BARD1
- BRCA1
- CAC1C
- CASP3
- CASP7
- CP19A
- CP1A2
- CP3A4
- KCNJ1
- CP3A7
- CTSR1
- CTSR2
Drug classes
- Antihypertensive Agents
- Calcium Channel Blockers
- Calcium-Regulating Hormones and Agents
- Cardiovascular Agents
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Membrane Transport Modulators
- Metabolic Side Effects of Drugs and Substances
- Vasodilator Agents
ATC classes
- C08C · SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Cross-references
Synonyms
- mibefradil dihydrochloride
- posicor
- Ro 40-5967
- Posicor 100
- Posicor 50
- Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer)
- Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics
- Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics
- Mibefradil [INN:BAN]
- Ro 40 5967
- Mibefradil (INN)
- Mibefradil HCl
- [(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] 2-methoxyacetate
- CHEMBL45816
- CHEBI:6920
- 27B90X776A
- MIBEFRADIL [INN]
- Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester
- Acetic acid, methoxy-, 2-(2-((3-(1H-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, (1S-cis)-
- MLS001056800
- Mibefradil dihydrochloride hydrate
- (1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl)(methyl)amino)ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
- (1S,2S)-2-(2-{[3-(1H-benzimidazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(propan-2-yl)-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
- AC1L1TOE
- SMR000326970
- Lopac-M-5441
- Ro 405967
- UNII-27B90X776A
- MIBEFRADIL [MI]
- MIBEFRADIL [VANDF]
- MIBEFRADIL [WHO-DD]
- Lopac0_000748
- SCHEMBL39551
- (1S-cis)-2-(2-((3-(1H-Benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate
- 2-(2-((3-(1H-Benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate (1S-cis)-
- MIBEFRADILDIHYDROCHLORIDE
- GTPL2522
- DTXSID1023318
Look up MIBEFRADIL in the interactive SynDRA portal →